Kanpo

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kanpo

What is Kanpo? (Composition: Sulpiride)

Property Description
Active ingredient Sulpiride (Rec.INN.)
Form Tablet, Capsule, Oral Solution, Intramuscular Injection
Pharmacological class Psycholeptic Agent (Neuroleptic)
High-level mechanism Selective Dopamine D₂/D₃ Receptor Antagonist
Origin Synthetic Organic Compound

Kanpo (Sulpiride): Classification and Identity

Kanpo is a medicinal product whose active constituent is the single ingredient Sulpiride, a chemically synthesized compound formally classified as a psycholeptic agent. This medicine falls within the broader group of antipsychotics (neuroleptic agents) and is chemically defined as a substituted benzamide derivative, a structure that distinguishes it from older neuroleptic classes. The INN (International Non-proprietary Name) for the active substance is Sulpiride.

Sulpiride's classification as an atypical antipsychotic is clinically recognized for its distinct selectivity. As a dopamine D2 receptor antagonist, its primary neurological action involves specifically targeting brain receptors related to dopamine to help regulate chemical signals.

Composition and Available Preparations

The chemical core of this medicine is Sulpiride, a single-ingredient product derived as a synthetic organic compound. A differentiating feature of the INN is its availability across diverse pharmaceutical preparations—notably the convenience of an oral solution and the rapid administration capability of an intramuscular injection, in addition to standard tablet and capsule forms. This variety in dosage forms is essential for flexible patient management.

General Purpose of Dopamine Modulators

The fundamental action is tied to its classification as a selective dopamine D2 and D3 receptor antagonist. By modulating the activity of these specific receptor sites, Sulpiride acts to promote a chemical balance within the central nervous system. This neurological modulation provides the high-level benefit of assisting in the general stabilization of mood and behavior in states of imbalance, a mechanism that is pharmacologically established to support improved neurological function.

Regulatory References

  1. EMA Medicines Search

What side effects are possible with Kanpo?

Possible Side Effects and Safety Information

This section details the officially documented adverse effects and safety characteristics of Kanpo (Sulpiride), organized according to regulatory classifications and findings from authoritative government health agencies. The profile is defined by frequency-classified adverse reactions, System-Organ-Class (SOC) groupings, and specific notes on serious adverse events.


Documented Adverse Reactions

The most frequently reported adverse reactions, classified as common in regulatory documents, primarily affect the nervous and endocrine systems. These include hyperprolactinaemia (elevated prolactin levels), sedation or drowsiness, and various extrapyramidal disorders such as tremor and parkinsonism. Other common effects include weight gain and constipation.

Reactions with a not known frequency, meaning their incidence cannot be estimated from available data, include rare but serious events. These documented serious risks involve the potential for Neuroleptic Malignant Syndrome (NMS), which is characterized by hyperthermia and muscle rigidity, and serious cardiac arrhythmias such as QT interval prolongation and Torsades de Pointes.


Safety Considerations and Restrictions

Official labeling addresses safety based on patient type and duration of exposure. There is a documented increased risk of mortality for older adults with dementia-related psychosis treated with this class of medicine. Furthermore, dose adjustments are often required for individuals with renal impairment.

Safety patterns related to treatment duration are noted: extrapyramidal symptoms are typically associated with the start of treatment or dose increases, while Tardive Dyskinesia is a recognized risk of long-term exposure. The medicine is officially restricted (contraindicated) in conditions like phaeochromocytoma and prolactin-dependent tumors.

Overdose and Emergency Response

Kanpo Overdose and When to Seek Help

The official regulatory profile for Kanpo (Sulpiride) overdose documents serious manifestations across the central nervous system and cardiovascular system.

Documented Overdose Presentations

Overdose may present with pronounced signs of CNS depression, ranging from over-sedation to a state of coma. Severe extrapyramidal symptoms (EPS) are commonly reported, including dystonia, trismus (lockjaw), and generalized increased muscle tone. Other documented signs include agitation, confusion, and hypotension.

Severe and Life-Threatening Outcomes

A critical concern in overdose is the potential for cardiotoxicity. Regulatory documents confirm the risk of QTc prolongation on an ECG, which can lead to life-threatening ventricular arrhythmias, including Torsade de pointes. Outcomes such as cardiac arrest are documented, and the development of Neuroleptic Malignant Syndrome (NMS) is noted as a potential severe complication.

Required Emergency Actions

Individuals who suspect an overdose must seek medical attention immediately. The regulatory documentation states that no specific antidote is known for Sulpiride. Management is therefore largely symptomatic and supportive, focusing on continuous cardiac monitoring due to arrhythmia risk, and may involve procedures such as administering activated charcoal or using anticholinergic drugs to manage severe EPS. Extended observation is required as coma can sometimes persist for several days.

Therapeutic Uses of Kanpo

What Kanpo Treats: Main Uses and Benefits

Kanpo (Sulpiride) is used across several core therapeutic domains where supportive relief for heightened symptomatic distress is needed, and may contribute to improved stability and comfort. The medicine is commonly applied in conditions characterized by periods of heightened symptoms related to psychosis and mood imbalance.

The medication is commonly used to help manage conditions such as schizophrenia, Major Depressive Disorder, and Dysthymia, and may be relevant for easing anxiety and tension. It is applied in addressing symptom clusters that may become intense or disruptive, including delusions, hallucinations, apathy, and emotional withdrawal.

“It provides supportive relief that helps patients cope more steadily with symptom fluctuations.”

The medicine is also relevant for easing symptoms related to heightened physiological activity, often used where psychological or neurotic distress is associated with somatic complaints, such as profound weakness (asthenia). It is also applied in clinical settings that involve severe behavioral disturbances in specific pediatric cases. This application supports the patient during difficult episodes by easing distress and contributes to maintaining functional stability.

Quick Fact: Relief for Affective and Psychotic Symptoms
This medicine is commonly used to help manage symptoms across both psychotic disorders (like managing thought disturbances) and affective disorders (like managing severe depression and lack of drive).

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Kanpo (Sulpiride) — official regulatory information

The eligibility for Kanpo (Sulpiride) is strictly defined by official regulatory documentation and is governed by age, specific pre-existing health conditions, and physiological states.

Category Regulatory Statement (Official Classification)
Populations for whom use is allowed Adults are the standard eligible group. Use in children (typically over 6 years) is limited, often only for specific, severe behavioral disturbances.
Populations for whom use is contraindicated Patients with known hypersensitivity to Sulpiride, prolactin-dependent tumors (e.g., breast cancer, prolactinoma), phaeochromocytoma, and conditions causing QT interval prolongation.
Age-related eligibility rules The medicine is not recommended for use in children under 6 years. Older adults require caution due to increased susceptibility to effects like sedation and postural hypotension.
Pregnancy and lactation eligibility status Not recommended during pregnancy unless the potential benefit justifies the risk. Not recommended while breastfeeding due to excretion into breast milk.

Condition-specific eligibility rules require caution or dose adjustment for patients with renal impairment, a history of epilepsy or convulsions, glaucoma, and Parkinson's disease (where use is generally discouraged unless absolutely necessary). The overall regulatory classification defines non-eligible groups through absolute contraindications and restricts use in other populations (e.g., pregnancy, organ impairment) through explicit cautionary guidance.

What should I know about interactions with other medicines?

Kanpo Interactions with other medicines and products

The interaction profile for Kanpo (Sulpiride) is based on pharmacodynamic restrictions and specific administration-timing rules documented in official regulatory labels.


Contraindicated Combinations

Official prescribing information designates combinations with Levodopa and other Dopamine Agonists as formally contraindicated. This prohibition is based on the documented pattern of reciprocal antagonism, where the two drug classes oppose each other’s primary effects. Use in the presence of prolactin-dependent tumours is also contraindicated.


Pharmacodynamic Restrictions

Co-administration is not recommended with medicines that prolong the QT interval (including specific antiarrhythmics and antipsychotics) or agents that induce bradycardia or hypokalaemia (such as certain Diuretics). These combinations increase the official risk of serious ventricular arrhythmias. Furthermore, combining Sulpiride with other CNS Depressants may enhance the additive effect of sedation. Alcohol use is mandatorily avoided as it potentiates the sedative effect of neuroleptics. Caution is also required when combining with Lithium due to increased risk of extrapyramidal reactions.


Pharmacokinetic and Timing Rules

A significant pharmacokinetic interaction occurs with Antacids and Sucralfate. Because co-administration officially decreases Sulpiride absorption, the regulatory labels mandate a timing rule: Sulpiride must be administered at least two hours before these gastrointestinal agents.

Mechanism of Action

Selective D2/D3 Receptor Blockade in the CNS

The primary feature of Kanpo's mechanism is the selective antagonism of postsynaptic Dopamine \mathbfD\mathbf2 and \mathbfD\mathbf3 receptors within the brain. This competitive blockade interrupts excessive dopamine signaling, resulting in the modulation of neural circuit activity and contributing to the drug's overall pharmacological effect.


Concentration-Dependent Dopamine Modulation

Sulpiride's action involves concentration-dependent properties: at low concentrations, it preferentially blocks highly sensitive presynaptic \mathbfD\mathbf2 autoreceptors. Removing this regulatory "brake" allows for an enhanced local release of dopamine, supporting the modulation of signaling and aiding the modulation of dopaminergic tone.


Mechanistic Specificity and Functional Constraints

Kanpo's mechanism is strictly confined to the dopamine system due to its lack of affinity for other widespread receptors, such as histamine H1 or muscarinic cholinergic sites. This high specificity dictates that the resulting physiological effects are purely dopamine-mediated. Antagonism in the pituitary's tuberoinfundibular pathway results in the physiological consequence of increased prolactin secretion.

Dosage and Administration Information

How to Use Kanpo (Sulpiride)

The use of Kanpo, whose active ingredient is Sulpiride, is governed by official guidelines specifying the approved routes, dosing schedules, and population-specific adjustments. The medicine is primarily administered orally in the form of tablets, capsules, or oral solution. The intramuscular injection is also recognized as an available administration route.

Standard Administration and Dosing

For adults, the total prescribed dose must be split and administered in two divided doses daily (twice daily), typically taken in the morning and early evening. The official starting dose often ranges from 400 mg to 800 mg daily, with established protocols suggesting a maximum daily limit of 2400 mg for treating certain conditions.

While Kanpo can be taken with or without food, standard instructions indicate administration be at least two hours before antacids or sucralfate to maintain proper absorption. Furthermore, scored tablets are designed to facilitate swallowing but are not intended to be divided into equal doses.

Usage Protocol for Specific Populations

The protocol dictates that dosing must be modified for patients with reduced kidney function. For individuals with renal impairment, the dose must be reduced or the interval between doses increased based on the degree of kidney function loss. Official documentation notes that clinical experience is insufficient to permit specific recommendations for children under 14 years of age. Treatment for chronic conditions often involves a long-term course, and discontinuation requires gradual dose reduction (tapering).

Recent Clinical Evidence

Recent Clinical Evidence for Kanpo

Clinical research on traditional Japanese Kampo medicine involves investigating the efficacy and safety of specific formulas in contemporary clinical settings. Unlike single-compound drugs, Kampo utilizes complex formulations containing multiple crude drugs, and evidence is often collected through randomized controlled trials (RCTs) and observational studies, primarily in Japan.


Key Areas of Research

Studies have concentrated on several areas where Kampo formulas may be used as complementary or standalone treatments. These include symptoms related to gastrointestinal disorders, the management of cancer-related fatigue, and the supportive treatment of various climacteric symptoms and chronic pain conditions.

  • Gastrointestinal Support: Research has examined certain formulas for their association with improvements in functional dyspepsia symptoms and in the supportive management of inflammatory bowel disease, often focusing on reducing patient-reported symptom severity.
  • Supportive Oncology Care: Clinical investigations have been conducted to evaluate if some Kampo preparations, when used alongside conventional treatments, are associated with improvements in quality of life measures, such as appetite loss and generalized fatigue, commonly reported during chemotherapy or radiation.
  • Psychoneurological Symptoms: Evidence is being developed regarding the use of specific formulas for the management of non-severe anxiety, sleep disturbances, and certain symptoms of mild cognitive impairment, particularly in older adult populations.

Scientific Evaluation

The scientific evaluation of Kampo medicines often addresses the need to standardize formula composition and to understand the mechanisms of action within a clinical context. Researchers use advanced analytical techniques to profile the active components. Current evidence suggests that for many conditions, the role of Kampo formulas is often supportive or complementary, and research continues to assess their overall clinical benefit and risk profile in diverse patient groups.

Frequently Asked Questions (FAQ)

Common questions about Kanpo (FAQ)

Q: Do I need a prescription from a doctor to get Kanpo?

Kanpo (Sulpiride) is classified by regulatory authorities as a Prescription Only Medicine (POM). This classification indicates that the medicine must be prescribed by a healthcare professional and obtained through a licensed pharmacy.

Q: Are there different types or brands of Kanpo?

The active ingredient in Kanpo is the single compound, Sulpiride, which may be sold under various brand names. Official documents note that this ingredient is formulated into different forms, such as tablets, capsules, oral solutions, and injections, to provide flexible options for administration.

Q: What is the difference between Kanpo and Kampo?

This is a key point of clarification. Kanpo (referring to the medicine with the active ingredient Sulpiride) is a single, chemically synthetic compound classified as an antipsychotic. Kampo (Kanpō) refers to the distinct, multi-herb traditional system of Japanese medicine, which is regulated separately.

Q: What happens if I forget to take a dose of Kanpo?

According to the official patient information leaflet, the instruction for a missed dose is to skip the missed dose and continue with the next scheduled dose. This guidance further specifies that a double dose should not be taken to make up for a forgotten dose.

Q: How does the government regulate Kanpo products?

Kanpo (Sulpiride) is regulated as a Prescription Only Medicine (POM) and a Psycholeptic Agent by government bodies like the EMA and PMDA. This classification ensures that the medicine meets mandatory standards for safety, efficacy, and quality control throughout its entire manufacturing and distribution process.

Q: Are there any foods or drinks I should avoid while using Kanpo?

Regulatory documents mandate the avoidance of alcohol when using Kanpo due to the risk of enhanced sedation, which is an additive central nervous system effect. No specific foods or non-alcoholic drinks are generally prohibited in the official regulatory guidance; however, consultation with a healthcare professional is always recommended to review all aspects of use.

Q: Can Kanpo affect my ability to drive or operate machinery?

Official patient information sheets often state that Kanpo may cause drowsiness and impaired concentration. Because of these potential effects, the official regulatory restriction is that patients who feel affected should not drive or operate machinery.

Q: How long does Kanpo stay in your system?

The time it takes for half the drug to be eliminated from the body, known as the elimination half-life, is approximately 6 to 8 hours. This information is based on clinical data reported in authoritative drug summaries.

Q: Can Kanpo be taken while using common over-the-counter pain relievers?

Regulatory guidance indicates that common over-the-counter pain relievers containing ingredients such as paracetamol or ibuprofen can typically be given. However, consultation with a healthcare professional is necessary before combining any medications, including non-prescription products.

Q: Does Kanpo interact with blood pressure medications?

Official product information notes that caution is required when combining Kanpo with medicines that can cause changes in heart rhythm, such as bradycardia or hypokalaemia. Due to this risk, review of all concurrent treatments by a healthcare professional is essential.

Q: Does Kanpo contain any common allergens like gluten or soy?

The inactive ingredients, known as excipients, vary by product form, and Kanpo tablets often include lactose. For individuals with known allergies to common excipients, reviewing the full patient information leaflet for the specific product’s detailed ingredient list is recommended.

Q: Do I need to change my diet while I am using Kanpo?

The most important restriction related to consumption is the mandatory avoidance of alcohol. Aside from this, official regulatory guidance does not prohibit any other specific food items or drinks.

Q: What makes Kanpo products vary in strength or formula?

Kanpo (Sulpiride) is a single active ingredient, but it is available in various strengths and forms (tablets, capsules, oral solution, and injection). These differences in strength and form provide flexible options for administration.

Q: What are the main differences between Kanpo and Western herbal supplements?

Kanpo (Sulpiride) is a single, chemically synthetic compound classified as a Prescription Only Medicine by health authorities. In contrast, Western herbal supplements are typically plant-derived, often containing multiple ingredients, and are usually sold over the counter with different regulatory oversight.

Q: Can Kanpo be purchased internationally, or is it restricted?

Kanpo is approved and available in many countries. However, as a Prescription Only Medicine, its movement across international borders is strictly controlled. Checking the regulations regarding the personal importation or exportation of medicines with each destination country's customs or health authority is necessary.

Q: Are there documented cases of overdose with Kanpo?

Overdose cases have been documented, and while the medicine has a relatively low acute toxicity, substantial amounts can lead to severe but reversible symptoms such as dystonia (involuntary muscle contractions). In rare cases, serious events like cardiac arrhythmias have been noted.

Q: Is it required to tell my healthcare provider I am using Kanpo?

Official guidance and safety principles indicate that patients are to inform their doctor, pharmacist, or other healthcare professional that they are taking Kanpo. This is especially important before starting any new medications (including non-prescription supplements) to allow for the review of potential interactions.

Q: Are there any specific safety monitoring recommendations for Kanpo users?

Official information implies the need for monitoring. Due to the risk of cardiac effects (such as QT prolongation), monitoring the patient’s cardiac status may be required. Additionally, dose adjustments are necessary for patients with reduced kidney function, suggesting that kidney monitoring is also important.

Q: What do authorities say about the purity and standardization of Kanpo?

As a Prescription Only Medicine approved by regulatory authorities, Kanpo (Sulpiride) must comply with mandatory manufacturing and quality standards. These standards ensure the drug's purity, potency, and batch-to-batch standardization as required for a pharmaceutical product.

Q: Is Kanpo meant to replace my existing prescriptions?

Kanpo may be used as the sole treatment (monotherapy) or as an add-on treatment (adjunctive therapy) alongside other medications. Its intended role in a treatment plan, whether standalone or complementary, depends on the condition being treated and the professional guidance of the prescriber.

Q: Does Kanpo expire, and what does the expiry date mean?

Yes, Kanpo products have an expiry date (or use-by date) indicated on the packaging. This date specifies the period during which the manufacturer guarantees the drug's full potency and safety, provided it is stored correctly as instructed.

Q: Does Kanpo cause any changes to appetite or weight?

Official regulatory documents list weight gain as a documented common side effect of Kanpo.

How should Kanpo be stored and disposed of?

The official storage and disposal requirements for Kanpo (Sulpiride) are set by regulatory authorities to ensure product stability and public safety.

Storage Requirements

The medicine must be stored at a temperature below 25°C to prevent degradation. It is required that the blister strip remains in the original outer carton to protect the contents from light and moisture, maintaining its stability until the expiry date. For safety, the product must always be stored out of the sight and reach of children.

Disposal Instructions

Official disposal rules mandate that unused or expired medicine must not be thrown away via household waste or wastewater. Instead, individuals are instructed to ask their pharmacist how to throw away medicines you no longer use to ensure proper environmental handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kanpo found in:

A-Z Index: